Calistoga Pharmaceuticals (Seattle, WA) a drug development startup focused on oncology and inflammation raised a $21M Series A. The deal was led by Frazier Healthcare Ventures and was joined by Alta Partners, Three Arch Partners and Amgen Ventures.

Calistoga (Seattle, WA) a spinout of Icos, is developing compounds targeting p110 delta for cancer, inflammatory and autoimmune indications raised $21M in a series A round. The financing was led by Frazier Healthcare Ventures and Alta Partners and joined by Three Arch Partners and Amgen Ventures.

BiPar (Brisbane, CA) an oncology company focused upon the use of PARP inhibitors and iodothyronine raised a $35M series B round. The deal was led by Domain Associates and joined by Vulcan Capital, Canaan Partners, PolyTechnos Asset Management and Quantum Technology Partners.

Immatics Biotechnologies (Germany) developing immunotherapies for renal cell and colorectal carcinoma raised €40 in Series B funding. Participants included Dietmar Hopp, National Technology Enterprises Co., KfW, 3i Group and Wellington Partners.

Proacta (San Diego, CA) a clinical stage oncology company closed a $35M Series B financing. Clarus Ventures, a new investor, led the round, and was joined by Delphi Ventures. Existing investors are Alta Partners, GBS Venture Partners and the New Zealand Venture Investment Fund as well as pharmaceutical companies Genentech and Roche.

Cylene Pharmaceuticals (San Diego, CA) a small molecule oncology drug discovery and development company closed a$44M Series C financing. The round was led by HBM BioVentures and Lilly Ventures.

Tigris Pharmaceuticals (Bonita, FL) developer of oncology therapies raised approximately $16M in a Series B financing. The round was led by NGN Capital along with Wexford Capital and Bushido Capital Partners.

Semafore Pharmaceuticals (Indianapolis, IN) a drug discovery and development company focused on small molecule modulators of the PI3 Kinase (PI3K) & PTEN cell signaling pathway has raised $9.5M in Series B funding led by Twilight Venture Partners.